Bispecific TGFβ/PD-L1 Binding Proteins for Dual Checkpoint Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting single immune checkpoint pathways, such as PD-L1 or TGFβ, are insufficient for all patients, leading to relapse and drug-resistant diseases, highlighting the need for agents that can block both PD-L1 and TGFβ signaling pathways to enhance T cell activation against cancer cells.
Innovation Solution
Development of engineered bispecific binding proteins that simultaneously bind to human TGFβ and PD-L1, comprising specific polypeptide chains that inhibit both pathways, promoting T cell activation and immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single immune checkpoint pathway targeting (PD-L1 or TGFβ) is used, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient leading to relapse and drug resistance
Solution Approach 1:
The patent combines two separate immune checkpoint targeting functions (PD-L1 binding and TGFβ binding) into a single bispecific binding protein. The protein contains both a PD-L1 binding domain and a TGFβ binding domain, allowing simultaneous inhibition of both immune checkpoint pathways through one therapeutic agent, thereby improving effectiveness while maintaining treatment simplicity
Solution Approach 2:
The bispecific binding protein is designed to perform multiple functions: it binds to PD-L1 to block the PD-1/PD-L1 immune checkpoint pathway, and simultaneously binds to TGFβ to block TGFβ signaling. This multi-functional design allows a single molecule to address multiple mechanisms of immune suppression, resolving the contradiction between effectiveness and complexity
2Reliability
If multiple immune checkpoint pathways are blocked simultaneously, then T cell activation is enhanced, but the molecular structure becomes more complex
Solution Approach 1:
The patent merges multiple immune checkpoint blocking functions into a single bisspecific binding protein structure. The protein simultaneously contains PD-L1 binding domains and TGFβ binding domains, enabling dual pathway inhibition through one molecular entity rather than requiring separate proteins, thus enhancing T cell activation while controlling structural complexity
Solution Approach 2:
The bispecific binding protein is constructed as a composite molecular structure combining different binding domains (PD-L1 binding domain and TGFβ binding domain) into one integrated protein. This composite design allows the molecule to exhibit multiple biological activities (blocking both PD-L1 and TGFβ pathways) while maintaining a unified, manageable protein structure
Data Source
AI summary
The present invention relates to bispecific binding proteins that bind TGFβ and PD-L1, and novel anti-PD-L1 antibodies, methods of making the bispecific binding proteins and antibodies, compositions comprising the bispecific binding proteins or antibodies, and methods of using the bispecific binding proteins for blocking TGFβ-mediated suppression of T cell activation, for blocking PD-L1-mediated suppression of T cell activation, and for treating cancer.